



Enabling cocrystallization of challenging systems: passing through a stable cocrystal solvate as a pathway to strenuous cocrystal forms

J.B. de Maere d'Aertrycke, R. Payen, L. Collard, K. Robeyns, Denise M. Croker, T. Leysens

Publication date

01-01-2020

Published in

Crystal Growth and Design;20 (3), pp. 2035-2043

Licence

This work is made available under the [CC BY-NC-SA 1.0](#) licence and should only be used in accordance with that licence. For more information on the specific terms, consult the repository record for this item.

Document Version

1

Citation for this work (HarvardUL)

de Maere d'Aertrycke, J.B., Payen, R., Collard, L., Robeyns, K., Croker, D.M. and Leysens, T. (2020) 'Enabling cocrystallization of challenging systems: passing through a stable cocrystal solvate as a pathway to strenuous cocrystal forms', available: <https://hdl.handle.net/10344/8669> [accessed 24 Jul 2022].

This work was downloaded from the University of Limerick research repository.

For more information on this work, the University of Limerick research repository or to report an issue, you can contact the repository administrators at ir@ul.ie. If you feel that this work breaches copyright, please provide details and we will remove access to the work immediately while we investigate your claim.

Article

Enabling cocrystallization of challenging systems: passing through a stable cocrystal solvate as a pathway to strenuous cocrystal forms

J.B. de Maere d'Aertrycke, R. Payen, L. Collard, K. Robeyns, D. Croker, and T. Leysens

Cryst. Growth Des., **Just Accepted Manuscript** • DOI: 10.1021/acs.cgd.9b01691 • Publication Date (Web): 13 Feb 2020

Downloaded from pubs.acs.org on February 18, 2020

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Enabling cocrystallization of challenging systems: passing through a stable cocrystal solvate as a pathway to strenuous cocrystal forms

J.B. de Maere d'Aertrycke^a, R. Payen^a, L. Collard^a, K. Robeyns^a, D. Croker^b, T.*

Leysens^a

^aInstitute of Condensed Matter and Nanosciences, Université Catholique de Louvain,

Place Louis Pasteur 1/L4.01.03, 1348 Louvain-la-Neuve, Belgium

^bSynthesis & Solid State Pharmaceutical Center (SSPC), Bernal Institute, University

of Limerick, Limerick V94 T9PX, Ireland

*corresponding author: jean-baptiste.demaere@uclouvain.be

ABSTRACT: Caffeine and maleic acid can form various cocrystal forms, which is a potential route to avoiding hydration issues of caffeine. This particular system was intensively studied as it not only shows co-crystal polymorphism, but also stoichiometrically diverse cocrystals with a 1:1 maleic acid: caffeine (MC) and a 1:2

1
2
3 maleic acid:caffeine (MC_2) form already identified. A cocrystallization process for MC
4
5
6
7 was already developed. However, a process leading to pure MC_2 remained a
8
9
10 challenge, as the stability zone of the MC_2 suspension is very narrow in most solvents.
11
12

13
14 In this paper, we propose an alternative crystallization pathway towards this crystal
15
16
17 form, passing through a stable solvate. Indeed, we identified a novel cocrystal solvate
18
19
20 of MC_2 ($MC_2.MeCN$) in acetonitrile at $9^\circ C$. This cocrystal solvate is characterized by a
21
22
23 large stability zone in the ternary phase diagram, and consequently, a crystallization
24
25
26
27 process leading to this form can easily be devised. Upon filtration, and exposure to
28
29
30 ambient atmosphere, $MC_2.MeCN$ is quickly de-solvated leading to the pure MC_2
31
32
33
34 cocrystal phase. In this contribution, we therefore show that cocrystal phases, which
35
36
37
38 are seemingly strenuous to crystallize from solution, can be accessed by thinking out-
39
40
41
42 of-the-box and using the properties of unexpected alternative phases.
43
44

45
46
47 Keywords: caffeine:maleic acid cocrystals – ternary phase diagram – crystal
48
49
50 engineering
51
52
53
54
55
56
57
58
59
60

1. Introduction

Many active pharmaceutical ingredients (API) exhibit unwanted physico-chemical properties, such as poor aqueous solubility, thermal degradation or polymorphic transition¹⁻³. A well-established tool to deal with such issues is to change the crystalline phase of the compound, either by salt or cocrystal formation⁴⁻⁶. Salts are formed through acid-base reactions and hence require an acid or basic group, implying that such technique cannot extend to all API's. On the other hand, cocrystal formation, the formation of a crystalline single phase material composed of two or more different molecular and/or ionic compounds in a stoichiometric ratio, involves any kind of molecular interaction (hydrogen bonding, π - π interactions, Van der Waals,...). Its application spectrum is therefor much wider⁶. Besides, its effectiveness to address undesired solid state-related properties of materials has already been well demonstrated. Cocrystallization has already been successfully used to enhance solubility and bioavailability of pharmaceutical compounds, or to avoid phase transformation phenomena, such as polymorphic transformation, crystal hydration or deliquescence⁵⁻⁹.

1
2
3 Different techniques are available on a laboratory scale to access cocrystals. (i)
4
5
6
7 Cocrystallization from the melt consists in heating a physical mixture of the two
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Different techniques are available on a laboratory scale to access cocrystals. (i) Cocrystallization from the melt consists in heating a physical mixture of the two coformers to form a liquid phase and cooling it down until recrystallization of the cocrystal phase occurs ¹⁰. (ii) Solid-state grinding of the two coformers is a very efficient method in which the two solid powders of coformers are mixed and ground at high frequency. A drawback of these two methods is the difficulty to isolate selectively the cocrystal phase from the other solid phases or impurities ^{11,12}. (iii) Solution based cocrystallization regroups all the different methods that involve the use of a solvent, namely ripening (or solvent mediated transformation), evaporation and cooling crystallization ¹³⁻¹⁶. Evaporative cocrystallization is performed by diluting both coformers in a volatile solvent and leaving the solution to evaporate. As the solvent evaporates, the concentration of both coformers increases until solubility of the cocrystal is reached and a solid cocrystal phase grows. Cooling crystallization consists in the formation of a solution of the two coformers, reaching supersaturation by cooling. In solvent mediated transformations, the coformers are left in suspension in conditions under which the cocrystal phase is the most stable phase. Cocrystallization occurs, in parallel to dissolution of both coformers ¹⁷.

1
2
3 Caffeine (Figure 1) is a pharmaceutical compound known to act as a central nervous
4
5
6
7 system stimulant and smooth muscle relaxant. It is used as a formulation additive to
8
9
10 boost the effect of analgesic remedies ²¹. Two polymorphs, α and β , have been
11
12
13 identified for caffeine: the α -form is most commonly encountered and the β -form only
14
15
16 exists at higher temperature. The two polymorphs are enantiotropically related with a
17
18
19 phase transition occurring at 145°C²². α -caffeine in itself is not ideal for pharmaceutical
20
21
22 formulation²³ as the channel-like structure of this crystal form traps water molecules.
23
24
25 The α -form is thus better described as a non-stoichiometric hydrate, containing
26
27
28 between 0.8 and 1 equivalent of water depending on ambient atmosphere humidity
29
30
31 and temperature. In 2005, Trask *et al.*, proposed to avoid water contamination of
32
33
34 caffeine taking a cocrystallization approach, successfully identifying five different
35
36
37 cofomers cocrystallizing with caffeine ²¹. Among these, maleic acid (Figure 1) showed
38
39
40
41
42 the particularity of forming two stoichiometrically diverse cocrystals.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 1. Detailed structure of caffeine (left) and maleic acid (right)

1
2
3
4 Due to this ability to form two stoichiometrically diverse cocrystals, the maleic
5
6
7 acid:caffeine system was intensively studied. A pure 1:1 maleic acid:caffeine cocrystal
8
9
10 (MC) phase could easily be obtained and single crystals isolated through solvent
11
12
13 evaporation using dichloromethane as a solvent ²¹. Interestingly, during the
14
15
16 development of a crystallization process for the MC form, a metastable polymorph of
17
18
19 this latter was encountered ²⁴. However, efforts in developing a crystallization process
20
21
22 leading to the pure 1:2 cocrystal material remained challenging. Attempts to obtain the
23
24
25 1:2 cocrystal form by solution crystallization often resulted in the formation of a mixture
26
27
28 of two crystal forms, either the 1:2 co-crystal and caffeine or a mixture of both the 1:2
29
30
31 (MC₂) and the 1:1 (MC) cocrystal phases ^{25–27}. Leysens et al., were able to obtain the
32
33
34 pure MC₂ form from solution using far out-of-equilibrium conditions ²⁴. Other successful
35
36
37 attempts were mentioned using ultrasound-assisted solution cocrystallization (USCC)
38
39
40 ²⁸, solvent free continuous crystallization (SFCC)²⁹, or electro-spray deposition (ESD)
41
42
43 ³⁰. Still, all these methods present critical drawback as they are either difficult to upscale
44
45
46 (ESD and USCC) or do not allow purification of the product (SFCC). Furthermore, all
47
48
49 are kinetically based, with no approach available to access thermodynamically the 1:2
50
51
52
53
54
55
56
57
58
59
60

1
2
3 phase in a robust manner. This is easily understood considering the extremely narrow
4
5
6
7 stability zone of the 1:2 phase in most solvents.
8
9

10 In this paper, we present an out-of-the-box approach to access this phase in a robust
11
12
13 manner. In our attempts to identify an alternative solvent allowing for a larger stability
14
15
16
17 zone of the 1:2 cocrystal, we stumbled upon a thermodynamically stable cocrystal
18
19
20 solvate working in acetonitrile. This form could easily be crystallized, and a very large
21
22
23 stability zone for this solvate was found. Furthermore, upon filtration, the solvate could
24
25
26
27 easily be de-solvated to yield the pure 1:2 cocrystal phase. We are here the first to
28
29
30 present a thermodynamic crystallization approach towards the 1:2 phase, passing
31
32
33 through a stable solvate phase. This is an original approach and shows that one can
34
35
36
37 use the diversity in the solid state to find thermodynamically robust processes, even
38
39
40
41 for those solid forms that are seemingly strenuous to crystallize.
42
43
44
45

46 2. Materials and methods

47
48
49 **Materials.** Caffeine (99% purity, CAS: 58-08-2), maleic acid (99% purity, CAS: 110-
50
51
52 16-7), acetonitrile (99% purity, CAS: 75-05-8) and ethyl acetate (99% purity, CAS: 141-
53
54
55 78-6) were purchased from Sigma-Aldrich and used without any further purification.
56
57
58
59 1:1 pure cocrystal phase was obtained by adding 390 mg of caffeine and 710 mg of
60

1
2
3 maleic acid (3 equivalents) to 10mL of ethyl acetate. The suspension was heated until
4
5
6 complete dissolution, subsequently cooled down to 9°C and left over-night. The
7
8
9 suspension was then filtered and washed with ethyl acetate. Pure 1:2 cocrystal phase
10
11 was obtained mixing 290 mg of caffeine and 180mg of maleic acid (1 equivalent) in
12
13
14 10mL acetonitrile. The suspension was heated up until complete dissolution and stored
15
16
17 at 9°C for two days. After two days, crystals appeared and the suspension was filtered
18
19
20 and washed. The powder was left to dry under ambient conditions, leading to the 1:2
21
22
23
24
25
26
27 phase.
28
29
30

31 **PXRD.** X-ray diffraction measurements were performed on a Siemens D5000
32
33
34 diffractometer equipped with a Cu X-ray source operating at 40 kV and 40 mA and a
35
36
37 secondary monochromator allowing to select the $K\alpha_1$ radiation of Cu ($\lambda = 1.5418 \text{ \AA}$). A
38
39
40 scanning range of 2θ values was applied from 2° to 50° at a scan rate of 0.6 min⁻¹
41
42
43 and a step of 0.02°. Simulated patterns of the known starting compounds were
44
45
46 calculated from their single crystal structures with Mercury 3.10 (version: August 2016).
47
48
49
50

51 **Single crystal XRD.** Single crystal X-ray diffraction was performed on a MAR345
52
53
54 image plate detector using Mo $K\alpha$ radiation (0.71073Å) generated by a Rigaku UltraX
55
56
57
58
59 18S rotating anode (Xenocs Fox3D mirrors). Prior to measurement the crystal was
60

1
2
3 flash cooled at 150 K in a N₂ flow. Data integration and reduction were performed by
4
5
6
7 CrysAlis^{PRO} (v1.171.35.19) and the implemented absorption correction was applied.
8
9
10 Structures were solved by direct method using the SHELXS-97 program and refined
11
12
13 by full-matrix least-squares on $|F|^2$ using SHELXL-2014^{31,32}. Non-hydrogen atoms
14
15
16 were refined anisotropically, and hydrogen atoms were placed on calculated positions
17
18
19 in riding mode with temperature factors fixed at 1.2 times U_{eq} of the parent atoms and
20
21
22
23
24 1.5 times U_{eq} for methyl groups.
25
26
27

28 **Determination of TPD in acetonitrile and ethyl acetate.** Ternary phase diagrams of
29
30 caffeine and maleic acid in different solvents were determined as follows: mixtures of
31
32 various composition in caffeine and maleic acid were prepared in 3 ml of either MeCN
33
34 or AcOEt. Samples were stored at a controlled temperature of 20°C or 9°C in a Polar
35
36 Bear Plus (Cambridge Reactor Design). Once the wanted temperature reached, vials
37
38 were seeded with ~3mg of 1:1 and 1:2 cocrystals. After five days, the solid phase was
39
40 filtered and its nature determined by PXRD, while a fraction of the supernatant was
41
42 sampled and analyzed by HPLC to determine caffeine and maleic acid concentration.
43
44
45
46
47
48
49
50
51
52
53
54
55
56 Even though the HPLC data allowed drawing the overall aspect of the TPD, for an
57
58
59
60

1
2
3 exact determination of eutectic points a more precise quantitative NMR (qNMR) based
4
5
6
7 approach was used.
8
9

10 **HPLC.** 150 μ L of supernatant was sampled, weighed and diluted 15 times in a 3:7
11
12 MeCN:H₂O solvent. Caffeine and maleic acid concentrations were dosed using the
13
14 following HPLC method: Device, Waters Alliance 2695. Column, Waters Sunfire C18
15
16
17
18 (4.6 \times 100 mm, 3.5 μ m). Detector, PDA 2998 (extraction at λ = 210 nm). T° = 40°C.
19
20
21 Injection volume: 5 μ L; Flow: 1.23 mL/min; Mobile phase A: H₂O + 0.1% H₃PO₄; Mobile
22
23
24
25 Phase B: CH₃CN + 0.1% H₃PO₄; Gradient: 0 min \rightarrow 10% B and 10%C; 1 min \rightarrow 10% B
26
27
28 and 10%C; 4.5 min \rightarrow 90% B and 10%C; 7 min \rightarrow 90% B and 10%C; Stop time: 7.5 min.
29
30
31
32
33

34 A calibration curve was determined prior to analyzing, using concentrations ranging
35
36
37
38 from 5 to 250 ppm (w/v) of either caffeine or maleic acid.
39
40

41 **qNMR.** 600 μ L of supernatant was sampled, weighed and left to evaporate in an NMR
42
43
44
45 tube. The solid residue was dissolved in 0.8mL of deuterated acetonitrile and quantified
46
47
48
49 by NMR. qNMR measurements were performed on a 300 MHz Bruker Avance, using
50
51
52 1,3,5-Trimethoxybenzene as an internal standard together with the compounds of
53
54
55
56 interest, dissolved in deuterated acetonitrile. The relaxation time d1 was set to 20 s to
57
58
59 ensure full relaxation of all protons, and 16 scans were performed for each sample.
60

1
2
3 **DSC.** DSC measurements were performed on a DSC 821 from Mettler Toledo.
4
5
6
7 Samples were ground manually in a mortar and 7mg placed in a perforated 40 μ L
8
9
10 aluminum crucible. The temperature was increased from 25°C to 180°C at a 10°C.min⁻¹
11
12
13
14 rate.

15
16
17 **Solubility curve determination.** Solubility curves of caffeine and maleic acid in MeCN
18
19
20 were determined using a Crystal 16 from Technobis. 1 mL solutions of various
21
22
23
24 concentration in caffeine or maleic acid were prepared and heated from -5 to 40°C at
25
26
27 a 0.02°C/min heating rate and stirred at 800rpm. Transmittance was recorded using a
28
29
30
31 laser beam to record the clear point of each vial.
32

33
34 **Upscaling the crystallization process for 1:2 maleic acid:caffeine cocrystal.**
35
36
37
38 Crystallizations were performed using an EasyMax 102 from Mettler Toledo in a 100
39
40
41 mL vessel. The stirring rate was set to 125 rpm and a temperature probe was put in
42
43
44 direct contact with the solution. A suspension of 1.83 mol/L of caffeine and 2.19 mol/L
45
46
47
48 of maleic acid in MeCN was first heated to 50°C and held for 1 hour to ensure complete
49
50
51
52 dissolution of the material. The solution was then cooled down to 9°C at a 0.3 K/min
53
54
55
56 rate. The suspension was left to equilibrate for 6 hours during which spontaneous
57
58
59 crystallization occurred, and filtration was subsequently performed on a sieve under
60

1
2
3 vacuum and products were characterized by PXRD. To determine the robustness of
4
5
6
7 the process, crystallization experiments were performed and seeded with different
8
9
10 crystal forms. Solid material was always extracted and subsequently analyzed by
11
12
13
14 PXRD.
15
16
17


18 **3. Results and discussions**

21 **3.1. Solvent selection**

22
23
24 Designing a robust cocrystallization process at scale is a challenge that requires an
25
26
27 accurate knowledge of the thermodynamics of the system under consideration ^{17,33}. As
28
29
30 three different components are involved in cocrystal formation, the solvent and the two
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Designing a robust cocrystallization process at scale is a challenge that requires an accurate knowledge of the thermodynamics of the system under consideration ^{17,33}. As three different components are involved in cocrystal formation, the solvent and the two cofomers, isothermal ternary phase diagrams (TPDs) are frequently used. These thermodynamic diagrams state the nature of the solid and liquid phases depending on the overall composition of the system at a given temperature ^{34–36}. In the current case, obtaining pure MC or MC₂ co-crystal phase as the only stable phase in suspension is rather difficult due to the large solubility difference encountered between maleic acid and caffeine in most solvents. This often leads to a skewed TPD with narrow stability zones for the cocrystal phases ¹⁶. By adjusting the relative solubility of both cofomers, a more symmetrical diagram can be expected (Figure 2). In the case studied here, we

1
2
3 hoped to identify a solvent that shows accessibility zones for the 1:1 and in particular
4
5
6
7 for the 1:2 cocrystal phase. Caffeine has a limited solubility in most solvents and
8
9
10 identifying a solvent showing comparable solubility towards caffeine and maleic acid is
11
12
13
14 not a straightforward task.



15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33 **Figure 2.** Theoretical TPD at a given temperature for a system of two cofomers A and
34
35
36 B, with strong solubility differences between both cofomers. By adjusting the
37
38 solubilities of both co-formers (e.g. by adjusting the temperature), a more symmetrical
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

solubility increases more rapidly with temperature. This is likely due to the higher mobilization of polar interactions at higher temperature. Indeed, between 9°C and 20°C, caffeine and maleic acid solubility are increased by 34% and 31% respectively in AcOEt, while the same temperature change in MeCN increases the solubility by 42% for caffeine and 63% for maleic acid. Based on these results, one could expect that the ternary phase diagram would exhibit a wider zone for the 1:2 cocystal crystallization at lower temperatures when working in MeCN. No significant differences are expected when working at different temperatures with AcOEt.




Figure 3. Solubility curves of caffeine and maleic acid in MeCN (left) and AcOEt (right)

3.2. Towards MC_2 cocrystallization




Figure 4. TPD of caffeine and maleic acid in AcOEt (up) and MeCN (down) at 20°C

The TPD in both solvents at 20°C show zones that allow the development of a robust cocrystallization process for caffeine, maleic acid as well as the 1:1 MC cocrystal form (Figure 4). Large stability zones containing two solid forms in suspension (M+MC; MC+MC₂; MC₂+C) can also clearly be observed. However, the zone where the 2:1 phase is the only stable phase in suspension is too narrow to be observed with the

precision at hand, confirming the difficulty to obtain this pure form by solvent crystallization. In addition, the determination of the different eutectic points by qNMR analysis shows that eutectics corresponding to mixtures of MC/MC₂ and MC₂/C are too close to be distinguished (Table 1). Indeed, MC/MC₂ and MC₂/C eutectic point coordinates are respectively [0.059 mol_{caf}.L⁻¹;0.191 mol_{mal}.L⁻¹] and [0.055 mol_{caf}.L⁻¹;0.190 mol_{mal}.L⁻¹] in AcOEt, and [0.20 mol_{caf}.L⁻¹;0.29 mol_{mal}.L⁻¹] and [0.19 mol_{caf}.L⁻¹;0.259 mol_{mal}.L⁻¹] in MeCN.

Table 1. Concentrations in caffeine and maleic acid determined by qNMR and nature of the solid phase in equilibrium at the eutectic points in AcOEt and MeCN at 20°C

Point	Solid phase composition	AcOEt – 20°C		MeCN – 20°C	
		x _{caf} [mol.L ⁻¹]	X _{mal} [mol.L ⁻¹]	x _{caf} [mol.L ⁻¹]	X _{mal} [mol.L ⁻¹]
A	M-MC	0.036±0.001	0.334±0.002	0.16±0.04	0.47±0.01
B	MC-MC ₂	0.059±0.001	0.191±0.001	0.20±0.01	0.29±0.01
C	MC ₂ -C	0.055±0.001	0.190±0.002	0.19±0.01	0.259±0.002

As for caffeine and maleic acid, MC solubility is higher in MeCN than in AcOEt. Indeed, the MC solubility product (K_{sp}) is estimated as 0.075 mol².L⁻² in MeCN and

1
2
3 0.012 mol².L⁻² in AcOEt.^a Similarly, K_{sp} for MC₂ is estimated as 0.0116 mol³.L⁻³ in
4
5
6
7 MeCN and 6.65*10⁻⁴ mol³.L⁻³. In both cases, the system is incongruent with respect to
8
9
10 the crystallization of the 1:1 phase, as one could expect looking at the solubility ratio
11
12
13 of caffeine to maleic acid (0.107 in AcOEt and 0.212 in MeCN). Nevertheless, the TPD
14
15
16 shows a strong increase in solubility for both caffeine and maleic acid upon addition of
17
18
19
20
21 the other component.
22

23
24 Ideally, we wanted to render these diagrams even more symmetrical, hoping to
25
26
27 increase the stability zone of the 2:1 phase. Based on the solubility curves, lowering
28
29
30 the temperature seemingly has a more important impact in MeCN with the solubility
31
32
33 ratio increasing from 0.212 to 0.243 going from 20°C to 9°C, whereas almost no impact
34
35
36 on the ratio (0.107 at 20°C and 0.104 at 9°C) is observed in AcOEt. Indeed, in the TPD
37
38
39 diagram in AcOEt at 9°C (Figure 5), the two eutectics delimiting the zone for pure MC₂
40
41
42 cocrystallization are once more close to each other (Table 2). In addition, the caffeine
43
44
45 to maleic acid concentration ratio of the different eutectics are similar at 20°C and 9°C,
46
47
48
49
50
51
52
53
54

55
56
57 ^a K_{sp} values have been estimated using eutectic point A for MC and eutectic point B
58
59 for MC₂
60

as was the case for the coformers' solubility ratio (point A: 0.11 at 20°C and 0.10 at 9°C – point B/C: 0.31/0.29 at 20°C and 0.25/0.31 at 9°C). This confirms that a decrease in temperature shifts the solubility lines in the TPD in a similar manner for all solid forms in AcOEt.




Figure 5. TPD of caffeine and maleic acid in AcOEt at 9°C

Table 2. Concentrations in caffeine and maleic acid determined by qNMR and nature of the solid phase in equilibrium at the eutectic points in AcOEt at 9°C

Point	Solid phase composition	AcOEt – 9°C	
		x_{caf} [mol.L ⁻¹]	X_{mal} [mol.L ⁻¹]
A	M-MC	0.0229±0.000 3	0.249±0.001

B	MC-MC ₂	0.0351±0.000 4	0.138±0.001
C	MC ₂ -C	0.0448±0.000 7	0.146±0.001

Based on the data above, we had more hope of strongly affecting the TPD by a temperature decrease using MeCN. To our surprise, constructing this diagram at 9°C led to the discovery of an unexpected new crystal form. Visually, the typical needle-shaped crystals one would expect for any of the known forms did not appear²⁴. Instead, translucent plate-like crystals came out of solution (Figure 6). These were analyzed by single crystal XRD and identified as a maleic acid:caffeine:acetonitrile (1:2:1) cocrystal solvate (MC₂.MeCN). The crystal structure was determined by single crystal XRD under a flow of liquid nitrogen at 150K to prevent desolvation. MC₂ and MC₂.MeCN do not show clear filiations in terms of crystal structure, however as they share a similar space group, it is possible that a topotactict desolvation process occurs. The study of the desolvation process has, however, not been studied in detail. In a similar mindset, co-crystal solvates have already been shown to be intermediates to produce specific polymorphs.¹⁸⁻²⁰





Figure 6. MC₂.MeCN cocrystal in MeCN at 9°C (left) and after 40 minutes in ambient atmosphere at 15°C (right) under microscope

The crystal structure obtained by single crystal XRD reveals the formation of a 1:2 maleic acid: caffeine solvated cocrystal. The cocrystal crystallizes in a monoclinic space group *Pc* (see Supporting Information 1). In the asymmetric unit, the two molecules of caffeine are linked to maleic acid through hydrogen bonds between the nitrogen with sp^2 hybridization of caffeine and the carboxylic function of maleic acid.

An internal hydrogen bond between the two carboxylic groups of maleic acid contributes to stabilize the conformation of maleic acid. Two hydrogen bonds, designated as D according to Etter's notation³⁷, form non-cyclic U-shaped trimers involving two caffeine and one maleic acid molecules (Figure 7a). The different U-shaped trimers are head-to-toe oriented, forming sequential alignment of caffeine

1
2
3 molecules and maleic acid molecules. Solvent molecules are located in the space left
4
5
6
7 between the different trimers, stabilized by Van der Waals interactions (Figure 7b).
8
9



10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33 **Figure 7.** Trimer constituting the MC₂.ACN cocrystal (left) and view of the packing along
34
35 the c-axis (right)
36
37
38
39

40
41 As was expected from the solubility study, the TPD in MeCN at 9°C is more
42
43 symmetrical than the one at 20°C due to the similar solubility of the cofomers. In
44
45 addition to the effect of temperature, the apparition of a solvated form changes the
46
47 equilibria between the different solid forms. Indeed, the MC₂ crystal form is no longer
48
49 thermodynamically stable at that temperature as the MC₂.MeCN is. Consequently, the
50
51 different eutectic points can clearly be distinguished (Table 3) and the different zones
52
53
54
55
56
57
58
59
60

for pure cocrystal formation, either MC or $MC_2 \cdot MeCN$, are well defined and accessible experimentally (Figure 8).

Table 3. Concentrations in caffeine and maleic acid determined by qNMR and nature of the solid phase in equilibrium at the eutectic points in MeCN at 9°C

Point	Solid phase composition	MeCN – 9°C	
		x_{caf} [mol.L ⁻¹]	X_{mal} [mol.L ⁻¹]
A	M-MC	0.08±0.01	0.3193±0.0004
B	MC-MC ₂	0.10±0.01	0.24±0.02
C	MC ₂ -C	0.11±0.01	0.136±0.003




Figure 8. TPD of caffeine and maleic acid in MeCN at 9°C

TPD determination at 9°C and 20°C also allowed determining the heat of dissolution (ΔH_d) of the MC crystal form in AcOEt and MeCN. Indeed, based on solubility data obtained experimentally, we were able to calculate the K_{sp} of MC at 20°C and 9°C in both solvents. Finally, we were able to determine ΔH_d using Van't Hoff equation that indicated the dissolution of MC is less endothermic in MeCN than in AcOEt (Table 4).


Table 4. Determination of MC heat of dissolution in AcOEt and MeCN

AcOEt		MeCN	
$K_{sp}^{20^\circ C}$	$1.20 \pm 0.02 \cdot 10^{-2}$	$K_{sp}^{20^\circ C}$	$8 \pm 2 \cdot 10^{-2}$
$K_{sp}^{9^\circ C}$	$5.7 \pm 0.1 \cdot 10^{-3}$	$K_{sp}^{9^\circ C}$	$2.6 \pm 0.2 \cdot 10^{-2}$
ΔH_d (kJ/mol)	47 ± 2	ΔH_d (kJ/mol)	67 ± 3

3.3. Crystallization process for MC₂ recovery

The findings above paved the way for the development of thermodynamically robust MC₂ cocrystallization process, starting from a 75mL clear supersaturated solution in conditions for which MC₂.MeCN is the thermodynamically stable form (Figure 9-left, black dot). Such a solution was prepared adding 2.67g of caffeine and 1.91g of maleic acid (1.2 equivalents) to 75mL of MeCN. The suspension was heated to 50°C and held for 1 hour to ensure complete dissolution of the material. The solution was then cooled down to 9°C at a 0.3 K/min rate. The suspension was left to equilibrate for 6 hours,

1
2
3 after which filtration was performed on a sieve under vacuum and products were
4
5
6 characterized by PXRD. To determine the robustness of the process, crystallization
7
8
9 experiments were performed and seeded with different crystal forms at the onset of
10
11
12 the isothermal hold at 9°C. Solid material were always extracted and subsequently
13
14
15 analyzed by PXRD. In principle, the thermodynamic outcome should be the 1:2
16
17
18 cocrystal solvate^b as it is the only stable form in suspension under these conditions.
19
20
21
22
23
24 Our results show that, no matter the type of seeding form used (M, C, MC, MC₂), this
25
26
27 solvate is always obtained at the end of the process, even if one does not seed,
28
29
30
31 implying this form is also the one that crystallizes out spontaneously (Figure 9-right).
32
33



34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55 ^b The MC₂ form was obtained as confirmed by PXRD analysis after filtration, as the
56
57
58 MC₂.MeCN form desolvates spontaneously upon exposure to ambient atmosphere.
59
60

1
2
3 **Figure 9.** Conditions for the upscaling experiment (left) and PXRD analysis of the
4
5
6
7 crystalline products (right)
8
9

10
11 A scale-up process was suggested for the MC₂ cocrystal form using these conditions.
12
13
14 To prepare seed material, an initial 4g slurry of MC₂.MeCN crystals in suspension was
15
16
17
18 left to equilibrate at 9°C for 2 days and used as a seeding material.^c
19
20

21
22 Then 3.56 g of caffeine and 2.55 g of maleic acid were added to 100ml of MeCN.
23
24
25 The solution was first heated up to 55°C to ensure complete dissolution of caffeine and
26
27
28 maleic acid. It was then cooled down to 9°C at a 2 K/h rate. After 15 minutes at 9°C,
29
30
31
32 the solution was seeded with the 4g seeding suspension and left to equilibrate for 6
33
34
35 hours. Upon filtration and drying, 2.01g of material (58% yield with respect to caffeine)
36
37
38
39 was recovered and analyzed by PXRD and DSC (see supporting information). The
40
41
42 quantity of material recovered accounts for 92% of the theoretical yield based on the
43
44
45 TPD, with the 8% loss explained by filtration and residues remaining in the
46
47
48
49 crystallization vessel.
50
51

52
53
54
55
56
57 ^c The composition used is once more identical to the one represented by the black dot
58
59 in Figure 9.
60

4. Conclusion

This study evidenced the importance of solvent and temperature in the development of a cocrystallization process. Under specific conditions, this can lead to crystallization of defined forms difficult to predict (solvate at lower temperature or cocrystals with 'original stoichiometry'). These forms can potentially give access to other forms phase transformations. In particular, we are the first to propose a robust way to obtain the 1:2 maleic acid:caffeine cocrystal. This latter form shows such a small stability zone in most solvents, that direct crystallization of this form is strenuous. Here we present an innovative pathway to this form, by co-crystallization of the 2:1 co-crystal solvate in MeCN. This solvate can easily be obtained by co-crystallization from solution, and desolvates to the 2:1 co-crystal form under ambient conditions, hereby offering a thermodynamic robust cocrystallization pathway to this form. This paper thus highlights the fact that one can use intermediate forms, to achieve seemingly difficult to get co-crystal forms.

5. Supporting information

- Crystal data and structure refinement for MC₂.MeCN
- DSC and PXRD characterization of process's product

This material is available free of charge via the Internet at <http://pubs.acs.org>.

6. Acknowledgements

The authors would like to thank the Université catholique de Louvain, Louvain-la-Neuve (Belgium), the University of Limerick, Limerick (Ireland) and the Doctiris program of Innoviris Brussels (Belgium) for practical and financial support.

7. References

- (1) Sarangi, M. K. A Brief Overview on Cocrystals and Their Pharmaceutical Applications. *Farmacia* **2014**, *62*, 824–839.
- (2) Aakeröy, C. B.; Forbes, S.; Desper, J. Using Cocrystals To Systematically Modulate Aqueous Solubility and Melting Behavior of an Anticancer Drug. *J. Am. Chem. Soc.* **2009**, *131*, 17048–17049. <https://doi.org/10.1021/ja907674c>.
- (3) Blagden, N.; de Matas, M.; Gavan, P. T.; York, P. Crystal Engineering of Active Pharmaceutical Ingredients to Improve Solubility and Dissolution Rates. *Adv. Drug Deliv. Rev.* **2007**, *59*, 617–630. <https://doi.org/10.1016/j.addr.2007.05.011>.
- (4) Qiao, N.; Li, M.; Schlindwein, W.; Malek, N.; Davies, A.; Trappitt, G. Pharmaceutical Cocrystals: An Overview. *Int. J. Pharm.* **2011**, *419*, 1–11. <https://doi.org/10.1016/j.ijpharm.2011.07.037>.

- 1
2
3
4 (5) Duggirala, N. K.; Perry, M. L.; Almarsson, Ö.; Zaworotko, M. J. Pharmaceutical
5 Cocrystals: Along the Path to Improved Medicines. *Chem. Commun.* **2016**, *52*,
6 640–655. <https://doi.org/10.1039/c5cc08216a>.
7
8
9 (6) Trask, A. V.; Motherwell, W. D. S.; Jones, W. Physical Stability Enhancement of
10 Theophylline via Cocrystallization. *Int. J. Pharm.* **2006**, *320*, 114–123.
11 <https://doi.org/10.1016/j.ijpharm.2006.04.018>.
12
13
14 (7) de Maere d'Aertrycke, J. B.; Robeyns, K.; Willocq, J.; Leysens, T.
15 Cocrystallization as a Tool to Solve Deliquescence Issues: The Case of L-Lactic
16 Acid. *J. Cryst. Growth*. <https://doi.org/10.1016/j.jcrysgro.2017.02.025>.
17
18
19 (8) Blagden, N.; Berry, D. J.; Parkin, A.; Javed, H.; Ibrahim, A.; Gavan, P. T.; Matos,
20 L. L. D.; Seaton, C. C. Current Directions in Co-Crystal Growth. *New J. Chem.*
21 **2008**, *32*, 1659–1672. <https://doi.org/10.1039/B803866J>.
22
23
24 (9) Schultheiss, N.; Newman, A. Pharmaceutical Cocrystals and Their
25 Physicochemical Properties. *Cryst. Growth Des.* **2009**, *9*, 2950–2967.
26 <https://doi.org/10.1021/cg900129f>.
27
28
29 (10) Karki, S.; Friščić, T.; Jones, W. Control and Interconversion of Cocrystal
30 Stoichiometry in Grinding: Stepwise Mechanism for the Formation of a
31 Hydrogen-Bonded Cocrystal. *CrystEngComm* **2009**, *11*, 470–481.
32 <https://doi.org/10.1039/B812531G>.
33
34
35 (11) Jayasankar, A.; Somwangthanaroj, A.; Shao, Z. J.; Rodríguez-Hornedo, N.
36 Cocrystal Formation during Cogrinding and Storage Is Mediated by Amorphous
37 Phase. *Pharm. Res.* **2006**, *23*, 2381–2392. [https://doi.org/10.1007/s11095-006-](https://doi.org/10.1007/s11095-006-9110-6)
38 [9110-6](https://doi.org/10.1007/s11095-006-9110-6).
39
40
41 (12) Shan, N.; Toda, F.; Jones, W. Mechanochemistry and Co-Crystal Formation:
42 Effect of Solvent on Reaction Kinetics. *Chem. Commun.* **2002**, No. 20, 2372–
43 2373. <https://doi.org/10.1039/B207369M>.
44
45
46 (13) Remenar, J. F.; Morissette, S. L.; Peterson, M. L.; Moulton, B.; MacPhee, J. M.;
47 Guzmán, H. R.; Almarsson, Ö. Crystal Engineering of Novel Cocrystals of a
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 Triazole Drug with 1,4-Dicarboxylic Acids. *J. Am. Chem. Soc.* **2003**, *125*, 8456–
4 8457. <https://doi.org/10.1021/ja035776p>.
5
6
7
8 (14) Fleischman, S. G.; Kuduva, S. S.; McMahon, J. A.; Moulton, B.; Bailey Walsh, R.
9 D.; Rodríguez-Hornedo, N.; Zaworotko, M. J. Crystal Engineering of the
10 Composition of Pharmaceutical Phases: Multiple-Component Crystalline Solids
11 Involving Carbamazepine. *Cryst. Growth Des.* **2003**, *3*, 909–919.
12 <https://doi.org/10.1021/cg034035x>.
13
14
15
16
17 (15) Horst, J. H. ter; Cains, P. W. Co-Crystal Polymorphs from a Solvent-Mediated
18 Transformation. *Cryst. Growth Des.* **2008**, *8*, 2537–2542.
19 <https://doi.org/10.1021/cg800183v>.
20
21
22
23 (16) Leyssens, T.; Horst, J. H. ter. Solution Co-Crystallisation and Its Applications.
24 *Multi-Compon. Cryst. Synth. Concepts Funct.* **2017**, 205–236.
25 <https://doi.org/10.1515/9783110464955-009>.
26
27
28
29 (17) Croker, D. M.; Davey, R. J.; Rasmuson, Å. C.; Seaton, C. C. Solution Mediated
30 Phase Transformations between Co-Crystals. *CrystEngComm* **2013**, *15*, 2044–
31 2047. <https://doi.org/10.1039/C2CE26801A>.
32
33
34
35 (18) Nicolai, B.; Espeau, P.; Céolin, R.; Perrin, M.-A.; Zaske, L.; Giovannini, J.;
36 Leveiller, F. Polymorph Formation from Solvate Desolvation. *J. Therm. Anal.*
37 *Calorim.* **2007**, *90*, 337–339. <https://doi.org/10.1007/s10973-007-8389-9>.
38
39
40
41 (19) Griesser, U. J. The Importance of Solvates. In *Polymorphism*; John Wiley &
42 Sons, Ltd, 2006; pp 211–233. <https://doi.org/10.1002/3527607889.ch8>.
43
44
45
46 (20) Kaur, R.; Cherukuvada, S.; Managutti, P. B.; Row, T. N. G. A Gallic Acid-
47 Succinimide Co-Crystal Landscape: Polymorphism, Pseudopolymorphism,
48 Variable Stoichiometry Co-Crystals and Concomitant Growth of Non-Solvated
49 and Solvated Co-Crystals. *CrystEngComm* **2016**, *18*, 3191–3203.
50 <https://doi.org/10.1039/c5ce01965f>.
51
52
53
54
55 (21) Trask, A. V.; Samuel Motherwell, W. D.; Jones, W. Pharmaceutical
56 Cocrystallization: Engineering a Remedy for Caffeine Hydration. *Cryst. Growth*
57 *Des.* **2005**, *5*, 1013–1021. <https://doi.org/10.1021/cg0496540>.
58
59
60


- 1
2
3
4 (22) Lehto, V.-P.; Laine, E. A Kinetic Study of Polymorphic Transition of Anhydrous
5 Caffeine with Microcalorimeter. *Thermochim. Acta* **1998**, *317*, 47–58.
6 [https://doi.org/10.1016/S0040-6031\(98\)00363-3](https://doi.org/10.1016/S0040-6031(98)00363-3).
7
8
9
10 (23) Griesser, U. J.; Burger, A. The Effect of Water Vapor Pressure on Desolvation
11 Kinetics of Caffeine 4/5-Hydrate. *Int. J. Pharm.* **1995**, *120*, 83–93.
12 [https://doi.org/10.1016/0378-5173\(94\)00416-3](https://doi.org/10.1016/0378-5173(94)00416-3).
13
14
15 (24) Leyssens, T.; Springuel, G.; Montis, R.; Candoni, N.; Veessler, S. Importance of
16 Solvent Selection for Stoichiometrically Diverse Cocrystal Systems:
17 Caffeine/Maleic Acid 1:1 and 2:1 Cocrystals - Crystal Growth & Design (ACS
18 Publications) <https://pubs.acs.org/doi/abs/10.1021/cg201581z> (accessed Apr
19 12, 2018).
20
21
22
23
24
25 (25) Guo, K.; Sadiq, G.; Seaton, C. C.; Davey, R.; Yin, Q. Co-Crystallization in the
26 Caffeine/Maleic Acid System: Lessons from Phase Equilibria - Crystal Growth &
27 Design (ACS Publications) <https://pubs.acs.org/doi/abs/10.1021/cg900885n>
28 (accessed Apr 12, 2018).
29
30
31
32
33 (26) Apshingekar, P. P.; Aher, S.; Kelly, A. L.; Brown, E. C.; Paradkar, A. Synthesis
34 of Caffeine/Maleic Acid Co-Crystal by Ultrasound-Assisted Slurry Co-
35 Crystallization. *J. Pharm. Sci.* **2017**, *106*, 66–70.
36 <https://doi.org/10.1016/j.xphs.2016.09.009>.
37
38
39
40
41 (27) Pagire, S.; Korde, S.; Ambardekar, R.; Deshmukh, S.; Dash, R. C.; Dhumal, R.;
42 Paradkar, A. Microwave Assisted Synthesis of Caffeine/Maleic Acid Co-Crystals:
43 The Role of the Dielectric and Physicochemical Properties of the Solvent.
44 *CrystEngComm* **2013**, *15*, 3705–3710. <https://doi.org/10.1039/C3CE40292D>.
45
46
47
48 (28) Aher, S.; Dhumal, R.; Mahadik, K.; Paradkar, A.; York, P. Ultrasound Assisted
49 Cocrystallization from Solution (USSC) Containing a Non-Congruently Soluble
50 Cocrystal Component Pair: Caffeine/Maleic Acid. *Eur. J. Pharm. Sci.* **2010**, *41*,
51 597–602. <https://doi.org/10.1016/j.ejps.2010.08.012>.
52
53
54
55
56 (29) Kulkarni, C.; Wood, C.; Kelly, A. L.; Gough, T.; Blagden, N.; Paradkar, A.
57 Stoichiometric Control of Co-Crystal Formation by Solvent Free Continuous Co-
58
59
60

- 1
2
3 Crystallization (SFCC). *Cryst. Growth Des.* **2015**, *15*, 5648–5651.
4 <https://doi.org/10.1021/acs.cgd.5b00806>.
5
6
7
8 (30) Patil, S.; Kulkarni, J.; Mahadik, K. Exploring the Potential of Electrospray
9 Technology in Cocrystal Synthesis. *Ind. Eng. Chem. Res.* **2016**, *55*, 8409–8414.
10 <https://doi.org/10.1021/acs.iecr.6b01938>.
11
12
13
14 (31) Sheldrick, G. M. A Short History of SHELX. *Acta Crystallogr. A* **2008**, *64*, 112–
15 122. <https://doi.org/10.1107/S0108767307043930>.
16
17
18 (32) Sheldrick, G. M. Crystal Structure Refinement with SHELXL. *Acta Crystallogr.*
19 *Sect. C Struct. Chem.* **2015**, *71*, 3–8.
20 <https://doi.org/10.1107/S2053229614024218>.
21
22
23
24 (33) Nehm, S. J.; Rodríguez-Spong, B.; Rodríguez-Hornedo, N. Phase Solubility
25 Diagrams of Cocrystals Are Explained by Solubility Product and Solution
26 Complexation. *Cryst. Growth Des.* **2006**, *6*, 592–600.
27 <https://doi.org/10.1021/cg0503346>.
28
29
30
31
32 (34) Chiarella, R. A.; Davey, R. J.; Peterson, M. L. Making Co-Crystals The Utility of
33 Ternary Phase Diagrams. *Cryst. Growth Des.* **2007**, *7*, 1223–1226.
34 <https://doi.org/10.1021/cg070218y>.
35
36
37
38 (35) Gagniere, E.; Mangin, D.; Puel, F.; Valour, J.-P.; Klein, J.-P.; Monnier, O.
39 Cocrystal Formation in Solution: Inducing Phase Transition by Manipulating the
40 Amount of Cocrystallizing Agent. *J. Cryst. Growth* **2011**, *316*, 118–125.
41 <https://doi.org/10.1016/j.jcrysgr.2010.12.027>.
42
43
44
45
46 (36) Oliveira, M. A.; Peterson, M. L.; Davey, R. J. Relative Enthalpy of Formation for
47 Co-Crystals of Small Organic Molecules. *Cryst. Growth Des.* **2011**, *11*, 449–457.
48 <https://doi.org/10.1021/cg101214m>.
49
50
51
52 (37) Etter, M. C. Encoding and Decoding Hydrogen-Bond Patterns of Organic
53 Compounds. *Acc. Chem. Res.* **1990**, *23*, 120–126.
54
55
56
57
58

59 For Table of Contents Use Only
60

1
2
3
4 Enabling cocrystallization of challenging systems: passing through a stable cocrystal
5
6
7 solvate as a pathway to strenuous cocrystal forms.
8
9

10
11 J.B. de Maere d'Aertrycke, R. Payen, L. Collard, K. Robeyns, D. Croker, T. Leyssens
12
13
14
15
16
17
18
19



44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Selecting the right solvent and temperature conditions allowed accessing a strenuous cocrystal form. Decreasing the temperature in acetonitrile, a new solvated cocrystal form is obtained. Upon exposure to ambient atmosphere, this form desolvates spontaneously and leads to the cocrystal form desired.



Figure 1. Detailed structure of caffeine (left) and maleic acid (right)

128x41mm (150 x 150 DPI)




Figure 2. Theoretical TPD at a given temperature for a system of two cofomers A and B, with strong solubility differences between both cofomers. By adjusting the solubilities of both co-formers (e.g. by adjusting the temperature), a more symmetrical phase diagram can be obtained.

244x96mm (150 x 150 DPI)




Figure 3. Solubility curves of caffeine and maleic acid in MeCN (left) and AcOEt (right)

342x113mm (150 x 150 DPI)





Figure 4. TPD of caffeine and maleic acid in AcOEt (up) and MeCN (down) at 20°C

160x167mm (150 x 150 DPI)






Figure 6. MC2.MeCN cocrystal in MeCN at 9°C (left) and after 40 minutes in ambient atmosphere at 15°C (right) under microscope

306x108mm (150 x 150 DPI)





Figure 7. Trimer constituting the MC2.ACN cocrystal (left) and view of the packing along the c-axis (right)

321x182mm (150 x 150 DPI)






Figure 9. Conditions for the upscaling experiment (left) and PXRD analysis of the crystalline products (right)

158x56mm (150 x 150 DPI)